Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × lutetium Lu 177 dotatate × Clear all

Phase

Phase 1/2 2 Phase 3 1 Phase 2 1

Status

Completed 2 Active not recruiting 2 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 18 Carboplatin 12 Radiotherapy 11 Paclitaxel 10 Fluorouracil 9 Rituximab 7 Gemcitabine 7 Drug Therapy 6 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Nivolumab 4 Docetaxel 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Methotrexate 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 Cetuximab 3 Bendamustine Hydrochloride 3 tislelizumab 2 ribociclib 2 parsaclisib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡